Skip to main content
. 2022 Mar 21;11(3):170–185. doi: 10.4103/EUS-D-21-00044

Table 2.

Outcomes of EUS-radiofrequency and ethanol ablation of pancreatic neuroendocrine tumors

Outcome EUS-RFA Ethanol P
Clinical success 85.2 (75.9-91.4), I2=0, 12 studies 82.2 (68.2-90.8), I2=10.1, 7 studies 0.65
Technical success 94.4 (88.3-97.4), I2=0, 13 studies 96.7 (90.8-98.8), I2=0, 7 studies 0.42
Adverse events 14.1 (7.1-26.3), I2=5, 12 studies 11.5 (4.7-25.4), I2=63%, 7 studies 0.7
Acute pancreatitis 7.8 (4.1-14.4), I2=0, 12 studies 7.6 (3.8-14.6), I2=0, 7 studies 0.95

Value are reported as pooled rate, 95% CI, I2 and number of studies. RFA: Radiofrequency; CI: Confidence interval